More on AMRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $18.04 |
|
|||
| Open | $17.86 | ||||
| 52 Wk High | $0.19 | ||||
| 52 Wk Low | $0.07 | ||||
| Day High | $18.39 | ||||
| Day Low | $17.82 | ||||
| P/E | N/A | ||||
| EPS | $-0.01 | ||||
| Volume | 2,118,219 | ||||
- FDA approves new Amneal iohexol injection strengths for imaging use
- Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
- Amneal Pharmaceuticals (AMRX) PT Raised to $23 at UBS
- Amneal to Report Second Quarter 2026 Results on July 30, 2026
- Alkermes terminates authorized generic supply deal with Amneal
- FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing
- FDA selects 7 companies for domestic drug manufacturing pilot
- Form DEFM14A Amneal Pharmaceuticals,
- EU panel backs Hopledo for Parkinson's motor fluctuations
- Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
Entities mentioned with AMRX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- 13D | View Related Stories »
- Show More...
